Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines

Bone Marrow Transplant. 2000 Aug;26(3):353-5. doi: 10.1038/sj.bmt.1702520.

Abstract

In comparison to bone marrow, umbilical cord blood has decreased intrinsic immune responsiveness allowing transplantation across HLA barriers with lower rates of graft-versus-host disease. However, laboratory models have also suggested that cord blood may be extremely sensitive to stimulation by cytokines. We report an adult recipient of an ex vivo expanded, HLA-mismatched, unrelated cord blood transplant who experienced a late extramedullary relapse while still in hematologic remission. Despite demonstrating immune tolerance on minimal immunosuppressive agents, a brief course of intravenous interleukin-2 resulted in rapid, aggressive graft-versus-host and graft-versus-leukemia reactions. This case highlights the potential of cytokine immunomodulation following cord blood transplantation, but also suggests caution in stimulating these cells.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / therapeutic use
  • Fetal Blood / cytology*
  • Fetal Blood / immunology
  • Graft vs Host Reaction / drug effects*
  • Graft vs Host Reaction / immunology
  • Graft vs Leukemia Effect / drug effects*
  • Graft vs Leukemia Effect / immunology
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Transplantation Chimera / immunology
  • Transplantation Tolerance / immunology

Substances

  • Adjuvants, Immunologic
  • Interleukin-2